Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Weiguo Su, Chunmei Bai et al.|The Lancet Oncology|2020

Cited by 193